Givinostat (ITF2357)

製品コードS2170

Givinostat (ITF2357)化学構造

分子量(MW):475.97

Givinostat (ITF2357)は一種の有効なHDAC阻害剤で、トウモロコシHD2、HD1BとHD1Aに作用して、無細胞試験でIC50値が10 nM、7.5 nMと16 nMそれぞれに分かれます。臨床2期。

サイズ 価格 在庫  
JPY 46076.16 あり
JPY 24477.96 あり
JPY 46076.16 あり
JPY 139668.35 あり

カスタマーフィードバック(3)

  • Representative confocal images of motor axons directly posterior to brains in third instar larvae co-expressing a synaptotagmin-e-GFP fusion protein (syt-eGFP) along with dTip60E431Q under the control of the pan neuronal elav-GAL4 driver reared on food treated with either no drug, ms-275, Givinostat.

    J Neurosci 2013 33(17), 7535-47. Givinostat (ITF2357) purchased from Selleck.

    Cells were treated with indicated HDAC inhibitors for 4 days and then cultured without drug for an additional 4 days. On day 8, HDAC inhibitors were added back to the culture for another 4 days. The percentage of GFP-positive cells was measured at days 4, 8 and 12. The concentrations of HDAC inhibitors used for the experiments are as follows: vorinostat, 1 uM; TsA, 200 nM; oxamflatin, 1 uM; scriptaid, 1 uM; belinostat, 200 nM; and givinostat, 200 nM. The fraction of GFP-positive cells was measured by flow cytometry at the indicated timepoints. The effect of HDAC inhibitors or anti-CD3 plus anti-CD28 antibodies over time was normalized to the effect of anti-CD3 plus anti-CD28 antibodies at day 2. Error bars represent SEM, n = 3. APHA, 3-(1-methyl-4-phenylacetyl-1H-2-pyrrolyl)-N-hydroxypropenamide.

    J Antimicrob Chemother 2014 69(1), 28-33. Givinostat (ITF2357) purchased from Selleck.

  • Western blot analysis of acetylated histone and histone. 0-10μM ITF2357 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Givinostat (ITF2357) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Givinostat (ITF2357)は一種の有効なHDAC阻害剤で、トウモロコシHD2、HD1BとHD1Aに作用して、無細胞試験でIC50値が10 nM、7.5 nMと16 nMそれぞれに分かれます。臨床2期。
特性 An orally active, potent inhibitor of histone deacetylases (HDACs).
ターゲット
HD1-B [1]
(Cell-free assay)
HD2 [1]
(Cell-free assay)
HD1-A [1]
(Cell-free assay)
7.5 nM 10 nM 16 nM
体外試験

In LPS-stimulated cultured human peripheral blood mononuclear cells (PBMCs), ITF2357 reduces the release of TNFα, IL-1α, IL-1β, and IFNγ, with IC50 of 10-25 nM, respectively. Using the combination of IL-12 plus IL-18, ITF2357 reduces IFNγ and IL-6 production with IC50 of 12.5-25 nM, independent of decreased IL-1 or TNFα. [1] ITF2357 is cytotoxic in multiple myeloma (MM) cell lines (RPMI8226, NCI-H929, JJN3, KMS 11, KMS 12, KMS 18, and KMS 20) and acute myelogenous leukemia (AML) cell lines (HL-60, THP-1, U937, KASUMI, KG-1, and TF-1), with IC50 of 200 nM. ITF2357 activates the intrinsic apoptotic pathway, upregulates p21 and downmodulates Bcl-2 and Mcl-1. ITF2357 inhibits the production of IL-6, VEGF, and IFNγ in mesenchymal stromal cells (MSCs) by 80-95%. [2] ITF2357 favors β-cell survival during inflammatory conditions. ITF2357 at concentrations of 25 and 250 nM increases islet cell viability, enhances insulin secretion, inhibits release of MIP-1α and MIP-2, reduces NO production and decreases apoptosis rates. [3]

体内試験 ITF2357 (1-10 mg/kg) reduces LPS-induced serum TNFα and IFNγ by more than 50% in mice. Anti-CD3-induced cytokines are not suppressed by ITF2357 in PBMCs in the circulation in mice. In concanavalin-A-induced hepatitis, ITF2357 (1 or 5 mg/kg) significantly reduces liver damage. [1] ITF2357 (10 mg/kg) significantly prolongs survival of severe combined immunodeficient mice inoculated with the AML-PS in vivo passaged cell line. [2] In a mouse model of closed head injury (CHI), ITF2357 (10 mg/kg) improves neurobehavioral recovery, decreases neuronal degeneration, reduces lesion volume, and induces glial apoptosis. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Enzymatic Assay for HDAC Inhibitory Activity of Synthetic Compounds:

The assay is performed by adding 100 μL substrate (2×105 cpm), 40 μL buffer (50 mM Tris-HCl, pH 8.0, 750 mM NaCl, 5 mM PMSF, 50% glycerol) and 95 μL distilled water to the crude cellular extract (5 μL). ITF2357 (50 μL) is added to test for HDAC inhibition. The mixture is incubated overnight at room temperature and the reaction quenched by adding 50 μL of a solution containing 259 μL 37% HCl and 28 μL acetic acid in 1 mL distilled water. The [3H]acetyl residues released from the substrate are separated by organic extraction with 600 μL of ethyl acetate, 200 μL of the organic phase is added to standard scintillation fluid, and radioactivity is measured by a beta-counter. Inhibition of HDACs is expressed as the concentration inhibiting 50% of the control activity (by comparing the radioactivity of the samples containing inhibitors to that of the control containing cellular crude extract alone).
細胞試験: [1]
+ 展開
  • 細胞株: peripheral blood mononuclear cells (PBMCs)
  • 濃度: 1 nM - 1 μM
  • 反応時間: 24 hours
  • 実験の流れ: After washing, the isolated PBMCs are resuspended in RPMI containing 5% FCS at 5×106/mL, added to a 50-mL conical polypropylene tube, and placed at 4 °C overnight. The PBMCs are resuspended the next morning and added to a 96-well flat microtiter plate (100 μL per well). ITF2357 is then added for inhibition studies, and the plates are incubated at 37 °C for 1 hour, after which the cells are stimulated with LPS or other stimulants in a final volume of 200 μL per well. The supernatants are removed after incubation at 37 °C for 24 hours, and frozen at -80 °C until assayed for cytokines.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: Mice. For LPS induction of serum cytokines: BALB/c; for anti-CD3-induced cytokines: CD1; for concanavalin A (Con A)-induced acute hepatitis: BALB/c or C57Bl6.
  • 製剤: Dissolved in water
  • 投薬量: 0.01-50 mg/kg
  • 投与方法: By gavage in 100 μL water.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 95 mg/mL (199.59 mM)
Ethanol 3 mg/mL (6.3 mM)
Water Insoluble
体内 順序で溶剤を入れること:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 475.97
化学式

C24H27N3O4.HCl.H2O

CAS No. 732302-99-7
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02851797 Not yet recruiting Duchenne Muscular Dystrophy Italfarmaco|inVentiv Health Clinical October 2016 Phase 3
NCT01901432 Recruiting Polycythemia Vera Italfarmaco October 2013 Phase 1|Phase 2
NCT01761292 Active, not recruiting Duchenne Muscular Dystrophy (DMD) Italfarmaco May 2013 Phase 1|Phase 2
NCT01761968 Recruiting Chronic Myeloproliferative Neoplasms Italfarmaco March 2013 Phase 2
NCT01557452 Terminated Juvenile Idiopathic Arthritis Italfarmaco|Parexel December 2011 --
NCT01261624 Terminated Polyarticular Course Juvenile Idiopathic Arthritis Italfarmaco October 2010 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

HDAC信号経路図

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Givinostat (ITF2357)を買う | Givinostat (ITF2357) ic50 | Givinostat (ITF2357)供給者 | Givinostat (ITF2357)を購入する | Givinostat (ITF2357)費用 | Givinostat (ITF2357)生産者 | オーダーGivinostat (ITF2357) | Givinostat (ITF2357)化学構造 | Givinostat (ITF2357)分子量 | Givinostat (ITF2357)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID